Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Suven Life Sciences Announces Completion of Patient Enrollment in Global Phase-3 Study of Masupirdine (SUVN-502) for Agitation Associated with Alzheimer s Dementia (AAD)".